Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19122771 | 0.91 | CREBBP (0.38) | CREBBPBRD4POLBCA2PTGS2 | |
| SCHEMBL90908 | 0.86 | CREBBP (0.40) | CREBBPBRD4CA2PTGS2CYP1A2 | |
| SCHEMBL13090773 | 0.86 | PTGS2 (0.36) | CREBBPBRD4POLBCA2PTGS2 | |
| SCHEMBL13591522 | 0.79 | PTGS2 (0.39) | CREBBPBRD4CA2PTGS2CYP1A2 | |
| SCHEMBL18643708 | 0.76 | GAA (0.38) | CREBBPBRD4POLBCA2PTGS2 | |
| SCHEMBL13817385 | 0.76 | USP2 (0.42) | CREBBPBRD4CA2PTGS2MAOB | |
| SCHEMBL17193797 | 0.76 | GAA (0.38) | CREBBPBRD4POLBCA2PTGS2 | |
| SCHEMBL17193805 | 0.76 | HTR2C (0.36) | CREBBPBRD4POLBCYP1A2CYP2A6 | |
| SCHEMBL22185345 | 0.76 | CA2 (0.38) | CREBBPBRD4CA2PTGS2CYP1A2 | |
| SCHEMBL10054032 | 0.76 | USP2 (0.37) | CREBBPBRD4CA2PTGS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129818-A1 | Compositions and Methods for Treatment of Cardiovascular Disease | CARMEL BIOSCIENCES, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129818-A1 | Compositions and Methods for Treatment of Cardiovascular Disease | CARMEL BIOSCIENCES, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2010124201-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE | INVASC THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | CREBBP 714/4885BRD4 97/4885POLB 2547/4885 |
| US-20120129818-A1 | Compositions and Methods for Treatment of Cardiovascular Disease | APOB, LDLR, APOL1 | CREBBP 3148/4885BRD4 3140/4885POLB 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.